ESRD Dialysis Billing 2026: The Bundled Payment System, Monthly Capitation Codes, and Case-Mix Adjustments Nephrology Practices Miss

By Rcmaxis Revenue Cycle Team  ·  September 2026  ·  13 min read

Dialysis billing simply doesn't work like the rest of outpatient medicine, and treating it as if it does is where most of the errors in this specialty originate. Medicare pays for most dialysis-related services through a bundled End-Stage Renal Disease Prospective Payment System — one per-treatment rate covering the dialysis session, most drugs, and most lab work — rather than itemized fee-for-service billing. Nephrologists managing dialysis patients bill separately under Monthly Capitation Payment codes rather than per-visit E/M codes, and the code selection depends on visit frequency and clinical complexity in a way that's genuinely easy to get wrong if a practice defaults to "however many visits happened this month" instead of actually checking the specific code's requirements.

This guide covers how the ESRD bundle actually works, the Monthly Capitation Payment codes nephrologists bill and where they get miscoded, the case-mix adjustments that change facility reimbursement per patient, and the documentation that supports accurate, defensible billing on both the facility and physician sides of a single dialysis patient's ongoing care.

How the ESRD Bundle Actually Works

Since the ESRD Prospective Payment System took effect, Medicare pays dialysis facilities a single bundled rate per dialysis treatment that covers the treatment itself, most injectable drugs previously billed separately, and routine laboratory tests. This is a fundamentally different payment logic than fee-for-service — the facility isn't billing individual line items for each drug and lab, it's billing a bundled rate that already assumes a certain basket of services was delivered.

The practical billing risk on the facility side is billing a drug or lab separately that's actually included in the bundle — an easy mistake for staff used to fee-for-service billing in other departments, and one that creates a real overpayment recoupment exposure when caught.

The bundle also includes an outlier payment mechanism for patients whose costs genuinely exceed the standard bundled rate due to unusual case complexity, but claiming an outlier payment requires specific documentation showing the actual cost drivers — a comorbidity, an unusual drug requirement — not just a general note that the patient "required more resources than typical." Facilities that don't build this documentation into the patient's ongoing chart, capturing it as costs actually occur rather than trying to reconstruct it at claim-submission time, tend to under-claim outlier payments they're genuinely entitled to.

Monthly Capitation Payment Codes: Where Nephrologists Underbill

Nephrologist management of dialysis patients bills under Monthly Capitation Payment codes, which are stratified by patient age and by the number of face-to-face visits during the month — and this is where a lot of legitimate revenue gets left uncaptured, because the code selection has to match actual documented visit frequency, not an assumption based on how the practice usually manages stable patients.

The reverse problem also costs money: practices that default to billing the highest MCP tier out of habit, without confirming that four or more visits actually happened and were separately documented that specific month, are building an overbilling pattern that surfaces the moment a payer compares billed MCP tier against actual visit documentation in the chart.

Case-Mix Adjustments and Why They Matter to Revenue

The ESRD PPS bundled rate isn't flat across every patient — it's adjusted for case-mix factors including patient age, body surface area, low body mass index, and specific comorbidities that increase the clinical complexity and cost of dialysis care. Facilities that don't actively track and document these case-mix factors are leaving legitimate rate adjustments unclaimed, not because the patients don't qualify, but because nobody captured the documentation that triggers the adjustment.

Comorbidity adjustments in particular require the qualifying condition to be documented consistently across the patient's medical record, not just noted once at enrollment into the facility's care. A comorbidity that qualified for an adjustment at initial workup but was never referenced again in subsequent documentation creates ambiguity about whether it's still an active, relevant condition — and ambiguity in supporting documentation is exactly what turns a legitimate adjustment into a denied or recouped claim during review.

OIG Scrutiny and Common Denial Patterns

ESRD billing has drawn OIG attention specifically around drug billing accuracy under the bundle — cases where separately billed drugs should have been included in the bundled rate, and cases involving inaccurate case-mix adjustment documentation that inflated the facility's payment rate. Reviews in this space typically run the standard federal lookback of several years, and recoupment exposure compounds quickly given how many treatments a single dialysis patient receives — typically three sessions weekly, every week, for years.

The most common ESRD-related denial and audit-finding patterns are: separately billed items that should have been bundled, MCP codes billed at a tier the documented visit count doesn't support, case-mix adjustments claimed without current supporting documentation, and non-routine lab billing coded as routine (or the reverse) in a way that either inflates or improperly captures charges outside the bundle. Every one of these is a documentation and coding-discipline issue, not a coverage dispute — which means they're also entirely preventable with the right checks built into monthly billing review rather than discovered during a payer audit years later.

Building that monthly review doesn't require a large compliance department — it requires a consistent, recurring check comparing what was billed against what the chart actually documents, run before the claims go out rather than after a payer's own review flags the discrepancy. A facility running this check monthly, on even a sample of claims, catches drift in MCP tier selection or case-mix documentation within weeks instead of discovering it years later during a full-scope federal audit with a much larger recoupment exposure attached. Given how many treatments a single dialysis patient generates every year, the compounding effect of catching an error early versus late in this specialty is larger than in almost any other area of billing. A coding habit that's off by even a small margin on a per-treatment basis, multiplied across three sessions a week for a full patient panel over a full year, turns into a discrepancy large enough that no reasonable explanation beyond a systemic process gap will satisfy a reviewer asking how it went unnoticed for so long — which is exactly why the monthly self-check, however small and routine it feels in isolation, is worth building into standard practice rather than treating as an optional extra step nobody quite gets around to.